EGFR and lung carcinoma: The identification of epidermal growth factor receptor (EGFR) gene mutations and the therapeutic efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in this subgroup of tumors established the basis for biomarker-driven lung cancer therapy [3].